Person playing on an app on their phone

Using the LyfeMD app to help Manage Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)


Written by: CDHF

Updated: January 29th, 2024

MASLD stands for Metabolic Dysfunction-Associated Steatotic Liver Disease, formally known as Non-Alcoholic Fatty Liver Disease (NAFLD).1 It’s a condition characterized by the accumulation of fat in the liver cells of people who drink little to no alcohol. MASLD is becoming increasingly common and is often associated with obesity, insulin resistance, and metabolic syndrome.

Managing MASLD typically involves lifestyle changes, such as adopting a healthy diet, increasing physical activity, and losing weight if necessary. Those with MASLD rarely have liver related symptoms, and commonly this condition is identified by abnormalities seen on blood work, done for routine purposes. Understandably, when confronted with news of liver disease, there are mixed responses of surprise, fear, and many questions about the diagnosis. If this is you, you may wonder what this diagnosis means, how and if it can be treated, and next steps of action.

People living with overweight or obesity, high blood sugar or high levels of fats in their blood, particularly triglycerides, are at higher risk for developing MASLD. Other risk factors include diet, lower engagement in physical activity, and mental health concerns such as poor mood or depression. Lifestyle management is the cornerstone treatment to improve your liver disease. However, lifestyle treatment is hard without support systems.

MASLD is a common condition, affecting over 20% of people in Canada and the United States. While it is unsettling to have been diagnosed with liver disease, fortunately, MASLD is treatable when it is diagnosed early. With commitment to therapy, it can reduce the risks of progression to advanced liver disease almost completely.

The LyfeMD app can help!

Developed by gastroenterologists, hepatologists and registered dietitians, the lifestyle therapies offered through LyfeMD were all created from evidence-based research as part of Ascend (Alberta’s Collaboration of Excellence for Nutrition in Digestive Disease), which brings together experts from the University of Calgary and University of Alberta led by Dr. Maitreyi Raman out of the Cumming School of Medicine.

lyfemd app

Through a customized dietary program developed just for you, you will receive a dietary plan that will help you start your journey to heal your liver. A personalized wellness program, will be able to support your wellness, mood and sleep which will help you reinforce your commitment to health. You will be able to choose physical activity programs that will help you with weight management and muscle development, which are protective to the liver. Each step of the way you will have the support of a LyfeMD coach to help you stay motivated and consistent, and you will have access to LyfeMD health experts if you have questions or doubts.

It’s essential to remember that while the LyfeMD app is a valuable tool for managing MASLD, it should not replace professional medical advice. Always consult with a healthcare provider for personalized guidance and treatment options for MASLD. Additionally, consider seeking guidance from a registered dietitian or nutritionist who can provide dietary recommendations tailored to your specific needs and condition.

To learn more about the LyfeMD app by visiting the LyfeMD website here.


  1. Rinella, Mary E.1; Lazarus, Jeffrey V.2,3; Ratziu, Vlad4; Francque, Sven M.5,6; Sanyal, Arun J.7; Kanwal, Fasiha8,9; Romero, Diana2; Abdelmalek, Manal F.10; Anstee, Quentin M.11,12; Arab, Juan Pablo13,14,15; Arrese, Marco15,16; Bataller, Ramon17; Beuers, Ulrich18; Boursier, Jerome19; Bugianesi, Elisabetta20; Byrne, Christopher D.21,22; Castro Narro, Graciela E.16,23,24; Chowdhury, Abhijit25,26; Cortez-Pinto, Helena27; Cryer, Donna R.28; Cusi, Kenneth29; El-Kassas, Mohamed30; Klein, Samuel31; Eskridge, Wayne32; Fan, Jiangao33; Gawrieh, Samer34; Guy, Cynthia D.35; Harrison, Stephen A.36; Kim, Seung Up37; Koot, Bart G.38; Korenjak, Marko39; Kowdley, Kris V.40; Lacaille, Florence41; Loomba, Rohit42; Mitchell-Thain, Robert43; Morgan, Timothy R.44,45; Powell, Elisabeth E.46,47,48; Roden, Michael49,50,51; Romero-Gómez, Manuel52; Silva, Marcelo53; Singh, Shivaram Prasad54; Sookoian, Silvia C.15,55,56; Spearman, C. Wendy57; Tiniakos, Dina11,58; Valenti, Luca59,60; Vos, Miriam B.61; Wong, Vincent Wai-Sun62; Xanthakos, Stavra63; Yilmaz, Yusuf64; Younossi, Zobair65,66,67; Hobbs, Ansley2; Villota-Rivas, Marcela68; Newsome, Philip N69,70;  on behalf of the NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology ():10.1097/HEP.0000000000000520, June 24, 2023. | DOI: 10.1097/HEP.0000000000000520

Related Articles:

View all News & Articles

girl holding the right side of her abdomen at the liver in pain

What is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)? Causes and Symptoms

Dietitian writing information down for a patient

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Testing, Managing, and Prevention

Person playing on an app on their phone

Using the LyfeMD app to help Manage Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)